FATE
FATE
NASDAQ · Biotechnology

Fate Therapeutics Inc

$2.39
-0.04 (-1.65%)
As of May 16, 2:11 AM ET ·
Financial Highlights (FY 2026)
Revenue
5.18M
Net Income
-106,329,779
Gross Margin
Profit Margin
-2,051.1%
Rev Growth
-59.0%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 63.6% 63.6%
Operating Margin -2,222.4% -2,000.2% -24.4% -27.5%
Profit Margin -2,051.1% -1,948.5% -25.6% -22.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 5.18M 12.63M 39.14M 43.52M
Gross Profit 24.91M 27.70M
Operating Income -115,118,731 -252,576,445 -9,536,619 -11,955,209
Net Income -106,329,779 -233,293,030 -10,010,485 -9,808,127
Gross Margin 63.6% 63.6%
Operating Margin -2,222.4% -2,000.2% -24.4% -27.5%
Profit Margin -2,051.1% -1,948.5% -25.6% -22.5%
Rev Growth -59.0% -59.0% +22.5% +8.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 13.35M 16.76M
Total Equity 48.97M 54.56M
D/E Ratio 0.27 0.31
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -105,078,840 -243,356,650 -16,322,152 -16,265,725
Free Cash Flow -10,981,777 -9,671,173